Navigation Links
BIO 2008: Germany on Cutting Edge in Biomanufacturing
Date:6/18/2008

SAN DIEGO, California, June 18 /PRNewswire/ -- Germany is on the cutting edge in biotechnology R&D and is a top player in large- and clinical-scale production. Companies located in Germany are poised to profit from the latest developments in biomanufacturing. These were the results of an expert panel, at the BIO International Convention (BIO 2008) in San Diego, California on June 18th. Invest in Germany co-chaired the panel along with the CEO of a major transatlantic biotech consultancy.

Dr. Barbara Esch opened the discussion, entitled "Biomanufacturing Solutions: Case Studies from Germany." She is responsible for the business development of biopharmaceuticals in the Corporate Division Biopharmaceuticals at the Boehringer Ingelheim GmbH in Ingelheim, Germany. Her presentation provided an overview of the biotechnology market in Germany, and offered examples of leading investment successes in Germany. Dr. Wiltrud Treffenfeldt, Director of Bioprocess Development, Dow AgroSciences LLC, discussed why the German contract manufacturing industry is uniquely positioned to create sustainable value in biopharmaceutical development and supply. Dr. Uwe Marx, Chief Scientific Officer (CSO) of Probiogen, a Berlin-based company that specializes in mammalian cell engineering and cell culture, discussed clinical biomanufacturing and how it serves the diverse needs of his company's client base.

Lastly Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius AG, talked about his perception of the current trends in biomanufacturing from the focus of an internationally leading process technology provider.

Angelika Geiger, Director of Invest in Germany's San Francisco office, and Steven Dickman, CEO of CBT Advisors chaired the panel. CBT Advisors is an international strategic consultancy with a focus on European and American biotech companies. Mr. Dickman also has experience in Germany. He previously did biochemical research at the German Cancer Research Center and served as correspondent for the journal Nature in Germany.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. Invest in Germany is at booth 711 throughout BIO 2008.

Eva Henkel

Invest in Germany

Phone: +49-30-200099-173

email: henkel@invest-in-germany.com

http://www.invest-in-germany.com


'/>"/>
SOURCE Invest in Germany
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Commencement 2008: Student innovation could improve data storage, magnetic sensors
3. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
4. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
5. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
6. Pharmaxis Aridol Authorised for Sale in Germany
7. World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment
8. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
9. Germany Hosts World Leading Medical Industry Fair
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):